Haleon Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by Haleon Plc (LSE/NYSE: HLN) covers the month of December 2025, with a specific reporting date of December 10, 2025. The document serves as a notification of transactions by Persons Discharging Managerial Responsibilities (PDMRs) in compliance with the UK Market Abuse Regulation. Haleon operates as a global leader in consumer health, managing brands across oral health, vitamins, pain relief, respiratory health, digestive health, and therapeutic skin health.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly a disclosure of insider share transactions and does not contain financial performance data.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details specific share acquisitions by two executives under the Company's Share Reward Plan:
- Adrian Morris (General Counsel): Acquired 35 Partnership Shares at £3.57201 each and received 35 Matching Shares at no cost on December 9, 2025.
- Tamara Rogers (Chief Marketing Officer): Acquired 35 Partnership Shares at £3.57201 each and received 35 Matching Shares at no cost on December 9, 2025.
Both transactions occurred on the London Stock Exchange (XLON).
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The content is limited to the statutory disclosure of the aforementioned share transactions.
Key Facts for Investor Verification
- Verify the total number of shares held by Adrian Morris and Tamara Rogers post-transaction to assess their total exposure.
- Confirm the current market price of Haleon ordinary shares relative to the transaction price of £3.57201.
- Review the terms of the Company's Share Reward Plan to understand the vesting schedule and conditions for the awarded Matching Shares.